Literature DB >> 33615198

Tryptophan Metabolism Regulates Proliferative Capacity of Human Pluripotent Stem Cells.

Shota Someya1, Shugo Tohyama1,2, Kotaro Kameda1, Sho Tanosaki1, Yuika Morita1, Kazunori Sasaki3, Moon-Il Kang3, Yoshikazu Kishino1, Marina Okada1, Hidenori Tani1, Yusuke Soma1, Kazuaki Nakajima1, Tomohiko Umei1, Otoya Sekine1, Taijun Moriwaki1, Hideaki Kanazawa1, Eiji Kobayashi2, Jun Fujita1,4, Keiichi Fukuda1.   

Abstract

Human pluripotent stem cells (hPSCs) have a unique metabolic signature for maintenance of pluripotency, self-renewal, and survival. Although hPSCs could be potentially used in regenerative medicine, the prohibitive cost associated with large-scale cell culture presents a major barrier to the clinical application of hPSC. Moreover, without a fully characterized metabolic signature, hPSC culture conditions are not optimized. Here, we performed detailed amino acid profiling and found that tryptophan (TRP) plays a key role in the proliferation with maintenance of pluripotency. In addition, metabolome analyses revealed that intra- and extracellular kynurenine (KYN) is decreased under TRP-supplemented conditions, whereas N-formylkynurenine (NFK), the upstream metabolite of KYN, is increased thereby contributing to proliferation promotion. Taken together, we demonstrate that TRP is indispensable for survival and proliferation of hPSCs. A deeper understanding of TRP metabolism will enable cost-effective large-scale production of hPSCs, leading to advances in regenerative medicine.
© 2021 The Author(s).

Entities:  

Keywords:  Cell Biology; Metabolomics; Stem Cell Research

Year:  2021        PMID: 33615198      PMCID: PMC7878994          DOI: 10.1016/j.isci.2021.102090

Source DB:  PubMed          Journal:  iScience        ISSN: 2589-0042


  6 in total

1.  Protocol for enhanced proliferation of human pluripotent stem cells in tryptophan-fortified media.

Authors:  Kotaro Kameda; Shota Someya; Jun Fujita; Keiichi Fukuda; Shugo Tohyama
Journal:  STAR Protoc       Date:  2022-04-22

2.  Scaffold-Free Tubular Engineered Heart Tissue From Human Induced Pluripotent Stem Cells Using Bio-3D Printing Technology in vivo.

Authors:  Yujiro Kawai; Shugo Tohyama; Kenichi Arai; Tadashi Tamura; Yusuke Soma; Keiichi Fukuda; Hideyuki Shimizu; Koichi Nakayama; Eiji Kobayashi
Journal:  Front Cardiovasc Med       Date:  2022-01-20

Review 3.  Human Engineered Heart Tissue Models for Disease Modeling and Drug Discovery.

Authors:  Hidenori Tani; Shugo Tohyama
Journal:  Front Cell Dev Biol       Date:  2022-03-31

4.  Purification of cardiomyocytes and neurons derived from human pluripotent stem cells by inhibition of de novo fatty acid synthesis.

Authors:  Sho Tanosaki; Tomohiko Akiyama; Sayaka Kanaami; Jun Fujita; Minoru S H Ko; Keiichi Fukuda; Shugo Tohyama
Journal:  STAR Protoc       Date:  2022-04-28

Review 5.  Scalable manufacturing of clinical-grade differentiated cardiomyocytes derived from human-induced pluripotent stem cells for regenerative therapy.

Authors:  Yuika Morita; Yoshikazu Kishino; Keiichi Fukuda; Shugo Tohyama
Journal:  Cell Prolif       Date:  2022-05-09       Impact factor: 8.755

Review 6.  The Present State and Future Perspectives of Cardiac Regenerative Therapy Using Human Pluripotent Stem Cells.

Authors:  Yusuke Soma; Yuika Morita; Yoshikazu Kishino; Hideaki Kanazawa; Keiichi Fukuda; Shugo Tohyama
Journal:  Front Cardiovasc Med       Date:  2021-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.